Search Results

• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

• EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT

  EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT

• Correlation of post SARS-COV-2 infection gut microbiome and gastrointestinal symptoms in pediatric and adolescent population

  Correlation of post SARS-COV-2 infection gut microbiome and gastrointestinal symptoms in pediatric and adolescent population

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

• Wingspan Stent System and Gateway PTA Balloon Catheter, HUD

  Wingspan Stent System and Gateway PTA Balloon Catheter, HUD

• Investigation Drug Study to Assess the Efficacy and Safety of NEXIUM for Treating Erosive Esophagitis

  A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years

• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

• Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)

  Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/​or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  AAML1831 - A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations